George Clinical, a clinical research organization (CRO) operating worldwide, has rebranded to become Emerald Clinical Trials.

Emerald Clinical Trials continues to focus on end-to-end services across all therapeutic areas designed to change lives⁠ while ⁠advancing innovations that help evolve global clinical research practices. With its track record in Oncology and Cardio-Renal-Metabolic (CRM) therapeutic areas, expertise in Asia Pacific, and global scientific leadership, Emerald Clinical Trials is a highly differentiated clinical CRO on the world stage. The company’s reach—operating directly in 42 countries and in 70 countries through partnerships—ensures seamless execution of clinical trials worldwide.

The new brand amplifies the work of Emerald Clinical Trials and highlights the breadth and depth of its experience to an even broader audience. It aims to emphasize a strong commitment to patients, customers, and partners.

“For the past two decades, Emerald Clinical Trials has been focused on delivering high-quality trials that combine a global reach with a high-touch approach. We offer the footprint and expertise of a large CRO with the personalized attention and flexibility of a smaller partner, ensuring that every client, from emerging biotech to top-tier pharma, receives the focused, hands-on support they need to de-risk their clinical programs,” said Mary Gunn, CEO, Emerald Clinical Trials. “This exciting transformation strengthens our position as a trusted partner in clinical trials while reaffirming our commitment to our clients and core values.”